BioPharmSignal logoBioPharmSignal

Biotech News

Intellia Therapeutics Announces Third Quarter 2026 Financial Results and Business Updates

Intellia (NTLA)IntelliaEarnings

On track to complete lonvo-z commercial readiness efforts in advance of March 10, 2027 PDUFA date New lonvo-z patient perspectives and Phase 1/2 durability data to be included in investor webcast and multiple presentations next week at ACAAI 2026 Completed enrollment in MAGNITUDE-2 Phase 3 clinical

Related news

NTLAIntellia2026-08-06 11:00 EST

Intellia Therapeutics Announces Second Quarter 2026 Financial Results and Business Updates

NTLAIntellia2026-07-30 12:00 EST

Intellia Therapeutics to Hold Conference Call on August 6 to Discuss Second Quarter 2026 Financial Results and Business Updates

SRPTSarepta Therapeutics2026-11-05 21:05 EST

Sarepta Therapeutics Announces Third Quarter 2026 Financial Results and Recent Corporate Developments

CRSPCRISPR Therapeutics2026-11-02 21:01 EST

CRISPR Therapeutics Provides Business Update and Reports Third Quarter 2026 Financial Results

SANASana Biotechnology2026-11-05 21:05 EST

Sana Biotechnology Reports Third Quarter 2026 Financial Results and Business Updates

SRPTSarepta Therapeutics2026-10-22 12:30 EST

Sarepta Therapeutics to Announce Third Quarter 2026 Financial Results

CRSPCRISPR Therapeutics2026-08-03 20:15 EST

CRISPR Therapeutics Provides Business Update and Reports Second Quarter 2026 Financial Results

SANASana Biotechnology2026-08-10 20:05 EST

Sana Biotechnology Reports Second Quarter 2026 Financial Results and Business Updates

ABEOAbeona Therapeutics2026-08-06 11:30 EST

Abeona Therapeutics® to Host Second Quarter 2026 Financial Results Conference Call on August 13, 2026

OCGNOcugen2026-07-28 20:01 EST

Ocugen to Host Conference Call on Thursday, August 6 at 8:30 A.M. ET to Discuss Business Updates and Second Quarter 2026 Financial Results

View all latest news

Intellia

In Vivo CRISPR Gene Editing Intellia Therapeutics develops potentially one-time medicines using CRISPR-based gene editing. Its lead programs edit disease-causing genes directly inside the body through systemically delivered therapies. Hereditary Angioedema Lonvoguran ziclumeran, or lonvo-z, is an in vivo gene-editing candidate designed...

Recent company news

NTLAIntellia2026-11-06 21:05 EST

Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

NTLAIntellia2026-11-05 13:00 EST

Intellia Therapeutics Announces Third Quarter 2026 Financial Results and Business Updates

NTLAIntellia2026-11-04 13:00 EST

Intellia Therapeutics Completes Enrollment in Phase 3 MAGNITUDE-2 Trial of Nexiguran Ziclumeran (Nex-z) for Patients with Hereditary Transthyretin Amyloidosis with Polyneuropathy (ATTRv-PN)

NTLAIntellia2026-11-03 13:00 EST

Intellia Therapeutics Announces Upcoming Nexiguran Ziclumeran (nex-z) Medical Congress Presentations

NTLAIntellia2026-10-29 12:00 EST

Intellia Therapeutics Announces Upcoming Lonvoguran Ziclumeran (Lonvo-z) Investor Event and Seven Presentations at ACAAI 2026

Stock data

Close
11.10 USD
Market cap
1.83B USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States